# Curi Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curi-bio

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.curibio.com
- Total disclosed funding: $10M
- Latest round: Series A (Dec 29, 2021)
- Investors on record: 3

## About

Founded in 2015 by CEO Nicholas Geisse and Elliot Fisher and based in Washington, US, Curi Bio, Inc., formerly NanoSurface Biomedical develops integrating human cells, systems, and data. In December 2025, Curi Bio, Inc. raised USD 10 million in series B funding led by new investor DreamCIS.

Curi Bio, Inc. provides a discovery platform that combines human stem cells, systems, and data in discovering new medicines. The firm also provides technologies and products that include NanoSurface Plates for structural maturation, Cytostretcher cell-stretching instruments, and Mantarray for 3D tissue contractility analysis, and it specializes in cardiac, musculoskeletal, and neuromuscular models.

## Funding rounds

- Series A, Dec 29, 2021, $4M — UTC Investment, DS Asset Management
- Series A, Mar 18, 2021, $6M — Dynamk Capital

## Investors

- Dynamk Capital (https://capitalatlas.ai/funds/dynamk-capital) — Series A
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series A
- DS Asset Management (https://capitalatlas.ai/funds/ds-asset-management) — Series A